Summary of Findings

🔴 Diabetes - Poorly Controlled

🔴 Dyslipidemia - Multiple Abnormalities

Overall Clinical Picture

1. Diabetes is not at goal - HbA1c 7.80% vs. target <7.0%. Medication review or intensification is warranted.
2. LDL is significantly elevated - At 160.58 mg/dL in a diabetic patient, statin therapy is strongly indicated (target LDL <70-100 mg/dL per most guidelines for diabetics).
3. Low HDL adds to cardiovascular risk and is common in metabolic syndrome/T2DM.
4. Non-HDL cholesterol of 183.30 (target <130 mg/dL in diabetics) further confirms high atherogenic burden.

Recommended Next Steps (for the treating physician)

• Diabetologist review - consider intensifying antidiabetic regimen (medication adjustment, dietary counseling)
• Statin therapy - if not already on it, high-intensity statin (e.g., atorvastatin 40-80 mg) is strongly indicated
• Lifestyle modification - low glycemic index diet, reduced saturated fat, regular aerobic exercise
• Cardiovascular risk assessment - given T2DM + dyslipidemia + age 54, consider ECG, stress test
• Repeat HbA1c in 3 months to assess treatment response

⚠️ This interpretation is for informational purposes. Please consult a qualified physician for medical advice and treatment decisions.

Treatment Plan - Mr. Sunil Mehrotra (54M, T2DM + Dyslipidemia)

Patient Profile Recap

• HbA1c: 7.80% (goal <7.0%)
• Fasting glucose: 158.5 mg/dL
• LDL: 160.58 mg/dL (optimal <100, for diabetics ideally <70)
• HDL: 34.7 mg/dL (low)
• Total Cholesterol: 218 mg/dL
• Non-HDL: 183.3 mg/dL
• No known CVD mentioned, but high cardiovascular risk profile

1. Glycemic Management

First-Line: Metformin (if not already on it)

• Metformin 500 mg twice daily with meals, titrate to 1000 mg BD over 4 weeks
• Most evidence-based, weight-neutral, cardioprotective
• Check renal function (eGFR) before prescribing; safe if eGFR >45

Add-On: Choose based on comorbidities

Harrison's 22E: "In individuals with type 2 DM and ASCVD or other ASCVD risk factors, a GLP-1 receptor agonist will reduce cardiovascular events." - Harrison's Principles of Internal Medicine 22E, p. 3271

2. Dyslipidemia Management (PRIORITY - EQUALLY IMPORTANT)

Statin Therapy - MANDATORY in this patient

• LDL target: <100 mg/dL (minimum); <70 mg/dL is preferred given diabetes + multiple risk factors
• That means he needs approximately a 57-70% LDL reduction

Goldman-Cecil Medicine: "People with diabetes with established ASCVD or an estimated 10-year cardiovascular risk of more than 7.5% should receive high-intensity statin treatment... sufficient to lower LDL cholesterol >50% from untreated baseline." - Goldman-Cecil Medicine, p. 1477

Note: Statins mildly increase HbA1c (hazard ratio ~1.2x risk of diabetes), but this is far outweighed by cardiovascular benefit per Harrison's 22E.

If LDL remains >70 on maximum statin:

• Add Ezetimibe 10 mg OD (further ~15-20% LDL reduction, safe, well-tolerated)
• Consider PCSK9 inhibitor (evolocumab/alirocumab) if very high risk and LDL still not at goal

Low HDL:

• HDL of 34.7 will improve with: glycemic control, aerobic exercise, smoking cessation (if applicable), and GLP-1 RA use
• Niacin/fibrates are generally no longer recommended routinely for low HDL in isolation

3. Lifestyle Modification (Non-Negotiable Foundation)

4. Blood Pressure Monitoring

• Target BP: <130/80 mmHg in diabetics
• If hypertensive: ACE inhibitor (e.g., ramipril 5-10 mg) or ARB (e.g., telmisartan 40-80 mg) is first-line - also provides kidney protection

5. Screening for Complications

6. Aspirin

• Not recommended for primary prevention in this patient (no prior CV event per available history)
• If he had a prior MI or stroke: Aspirin 75-81 mg daily is indicated

Summary Prescription

⚠️ This is a clinical education summary based on Harrison's Principles of Internal Medicine (22nd Ed., 2025), Goldman-Cecil Medicine, and current evidence. All prescribing decisions must be made by a qualified physician who has examined the patient, reviewed a complete history, and checked for drug interactions and contraindications.